[go: up one dir, main page]

AU2003299990A1 - Mbcats as modifiers of the beta-catenin pathway and methods of use - Google Patents

Mbcats as modifiers of the beta-catenin pathway and methods of use

Info

Publication number
AU2003299990A1
AU2003299990A1 AU2003299990A AU2003299990A AU2003299990A1 AU 2003299990 A1 AU2003299990 A1 AU 2003299990A1 AU 2003299990 A AU2003299990 A AU 2003299990A AU 2003299990 A AU2003299990 A AU 2003299990A AU 2003299990 A1 AU2003299990 A1 AU 2003299990A1
Authority
AU
Australia
Prior art keywords
mbcats
modifiers
beta
methods
catenin pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299990A
Other versions
AU2003299990A8 (en
Inventor
Helen Francis-Lang
Kim Lickteig
Richard Benn Abegania Ventura
Christopher G. Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2003299990A8 publication Critical patent/AU2003299990A8/en
Publication of AU2003299990A1 publication Critical patent/AU2003299990A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003299990A 2002-12-30 2003-12-29 Mbcats as modifiers of the beta-catenin pathway and methods of use Abandoned AU2003299990A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43697402P 2002-12-30 2002-12-30
US60/436,974 2002-12-30
PCT/US2003/041404 WO2004061123A2 (en) 2002-12-30 2003-12-29 Mbcats as modifiers of the beta-catenin pathway and methods of use

Publications (2)

Publication Number Publication Date
AU2003299990A8 AU2003299990A8 (en) 2004-07-29
AU2003299990A1 true AU2003299990A1 (en) 2004-07-29

Family

ID=32713115

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299990A Abandoned AU2003299990A1 (en) 2002-12-30 2003-12-29 Mbcats as modifiers of the beta-catenin pathway and methods of use

Country Status (2)

Country Link
AU (1) AU2003299990A1 (en)
WO (1) WO2004061123A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008107900A2 (en) * 2007-03-07 2008-09-12 Yeda Research And Development Co. Ltd. Compositions and methods for modulating cell migration

Also Published As

Publication number Publication date
AU2003299990A8 (en) 2004-07-29
WO2004061123A3 (en) 2004-12-09
WO2004061123A2 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
AU2003213606A1 (en) MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003275311A1 (en) Solid micro-perforators and methods of use
AU2003248879A1 (en) RABS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003272400A1 (en) Syts as modifiers of the p21 pathway and methods of use
AU2003251799A1 (en) Mchks as modifiers of the chk1 pathway and methods of use
AU2003295881A1 (en) Lamps as modifiers of the p53 pathway and methods of use
AU2003299990A1 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003217851A1 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
AU2003265263A1 (en) ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003274911A1 (en) Mrbs as modifiers of the rb pathway and methods of use
AU2003303094A1 (en) MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003295928A1 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003213662A1 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2002361654A1 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003251826A1 (en) Mp21s as modifiers of the p21 pathway and methods of use
AU2003258095A1 (en) MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
EP1578945A3 (en) Cct6s as modifiers of the rb pathway and methods of use
AU2003294499A1 (en) Rhebs as modifiers of the rb pathway and methods of use
AU2003213693A1 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
AU2003213665A1 (en) Lgals as modifiers of the chk pathway and methods of use
AU2003248876A1 (en) MP53S AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003278811A1 (en) LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003215004A1 (en) Msrebps as modifiers of the srebp pathway and methods of use
AU2003223208A1 (en) MP21s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
EP1540333A4 (en) Maxs as modifiers of the axin pathway and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase